Olthuis H P, Stienstra S, Puylaert C E, Verhagen C M, Bär B M
Red Cross Blood Bank Nijmegen, The Netherlands.
Transfus Sci. 1993 Apr;14(2):195-7. doi: 10.1016/0955-3886(93)90031-O.
Platelet refractoriness in treatment of multitransfused patients with haematologic malignancies can be delayed or prevented by transfusing leukocyte-poor platelet concentrates. Absence of consensus about the number of residual leukocytes that leads to a delay or prevention of HLA-antibody formation, may be based on a lack of sampling for determination of leukocyte contamination levels in platelet concentrates. From data presented in this study we conclude that if every preparation of platelets is also tested for platelet count, it reduces costs when the pheresis platelets can be split. Transfusion of platelets in patients can also be better evaluated.
通过输注少白细胞的血小板浓缩物，可延缓或预防血液系统恶性肿瘤多次输血患者的血小板输注无效。对于导致HLA抗体形成延迟或预防的残余白细胞数量缺乏共识，可能是由于缺乏对血小板浓缩物中白细胞污染水平进行测定的采样。从本研究提供的数据中我们得出结论，如果对每份血小板制剂也进行血小板计数检测，那么当单采血小板可以分离时，可降低成本。对患者的血小板输注情况也能进行更好的评估。
